2021 - Reliable identification of cardiac liability in drug discovery using automated patch clamp: Considerations and best practices for high throughput recordings of NaV 1.5
Patchliner and SyncroPatch 384i (a predecessor model of SyncroPatch 384) Physiology 2021 (2 MB)
For reliable identification of cardiac safety risk, compounds should be screened for effects on cardiac ion channels in addition to hERG including NaV1.5 and CaV1.2 Automated patch clamp (instruments are increasingly adopted for cardiac safety measurements but cross site and cross platform comparisons of IC50 values has identified the need for standardized
protocols for reliable pharmacology In this study, we identified different parameters that might affect IC50s of compounds on NaV1.5 peak and late currents recorded using APC.
Back to Overview